OCGN Ocugen Inc
Price (delayed)
$0.5466
Market cap
$159.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$133.3M
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier
Highlights
OCGN's quick ratio is up by 18% year-on-year and by 10% since the previous quarter
The EPS has grown by 23% year-on-year but it has declined by 11% since the previous quarter
The net income rose by 14% YoY but it fell by 6% QoQ
Ocugen's gross profit has decreased by 33% YoY and by 14% QoQ
OCGN's revenue is down by 33% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of OCGN
Market
Valuations
Earnings
Shares outstanding
292.01M
Market cap
$159.62M
Enterprise value
$133.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.37
Price to sales (P/S)
36.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.87
Revenue
$4.06M
Gross profit
$4.06M
Operating income
-$54.76M
Net income
-$54.01M
EBIT
-$54.01M
EBITDA
-$51.19M
Free cash flow
-$45.53M
Per share
Balance sheet
Liquidity
EPS
-$0.2
EPS diluted
-$0.2
Free cash flow per share
-$0.17
Book value per share
$0.1
Revenue per share
$0.01
TBVPS
$0.3
Total assets
$82.44M
Total liabilities
$52.81M
Debt
$32.5M
Equity
$29.63M
Working capital
$40.09M
Debt to equity
1.1
Current ratio
2.86
Quick ratio
2.72
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-1,262.3%
Gross margin
100%
Net margin
-1,331.9%
Operating margin
-1,350.4%
Return on assets
-91.3%
Return on equity
-183.9%
Return on invested capital
-276.5%
Return on capital employed
-88.8%
Return on sales
-1,331.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCGN stock price
How has the Ocugen stock price performed over time
Intraday
-1.76%
1 week
-7.36%
1 month
-18.67%
1 year
-41.99%
YTD
-32.1%
QTD
-32.1%
Financial performance
How have Ocugen's revenue and profit performed over time
Revenue
$4.06M
Gross profit
$4.06M
Operating income
-$54.76M
Net income
-$54.01M
Gross margin
100%
Net margin
-1,331.9%
Ocugen's gross profit has decreased by 33% YoY and by 14% QoQ
OCGN's revenue is down by 33% YoY and by 14% from the previous quarter
The net margin has contracted by 27% YoY and by 22% from the previous quarter
The company's operating margin fell by 24% YoY and by 21% QoQ
Growth
What is Ocugen's growth rate over time
Valuation
What is Ocugen stock price valuation
P/E
N/A
P/B
5.37
P/S
36.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.87
The EPS has grown by 23% year-on-year but it has declined by 11% since the previous quarter
The price to book (P/B) is 59% less than the last 4 quarters average of 13.1 and 35% less than the 5-year quarterly average of 8.2
The equity fell by 27% QoQ and by 27% YoY
The price to sales (P/S) is 37% less than the last 4 quarters average of 57.8
OCGN's revenue is down by 33% YoY and by 14% from the previous quarter
Efficiency
How efficient is Ocugen business performance
OCGN's ROE has dropped by 79% year-on-year and by 28% since the previous quarter
The ROIC has grown by 32% YoY and by 21% from the previous quarter
The return on sales has declined by 27% year-on-year and by 22% since the previous quarter
The return on assets has declined by 17% year-on-year and by 8% since the previous quarter
Dividends
What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCGN.
Financial health
How did Ocugen financials performed over time
OCGN's total assets is 56% greater than its total liabilities
The company's total liabilities has surged by 148% QoQ and by 120% YoY
OCGN's total assets is up by 33% since the previous quarter and by 28% year-on-year
The debt is 10% more than the equity
The equity fell by 27% QoQ and by 27% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.